Gene Variants Can Alter Glucose Absorption and Cardiometabolic Risks Interview with:

Scott David Solomon, MD Director, Noninvasive Cardiology Professor, Harvard Medical School Brigham and Women's Hospital

Dr. Solomon

Scott David Solomon, MD
Director, Noninvasive Cardiology
Professor, Harvard Medical School
Brigham and Women’s Hospital What is the background for this study? What are the main findings? 

Response: The sodium glucose transport proteins are known to be important in regulating uptake of glucose. SGLT-1 is predominantly located in the gut and is responsible for uptake of glucose and galactose in the small intestine. Individuals born with severe mutations of this gene have severe malabsorption syndrome.

We looked at genetic variants that lead to reduced function of the protein, but not complete loss of function, in a large cohort of individuals in the NIH funded Atherosclerosis Risk in Communities Study. We found that those with mutations in the gene had reduced glucose uptake, as measured by an oral glucose tolerance test, as well as less obesity, diabetes, heart failure and death. What should readers take away from your report?

Response: These findings suggest that genetic variation can play a role in our propensity to absorb glucose in the gut and individuals with particular mutations might have a lower risk of cardio metabolic disease. These findings suggest that inhibiting the SGLT-1 receptor might be a useful therapeutic approach. What recommendations do you have for future research as a result of this work? 

Response: It will be important to look at effects of mutations in SLGT-1 in other populations, and to determine if SLGT-1 inhibitors might provide similar benefits.

Disclosure: ARIC was funded by the NHLBI. I have received  received research grants to my institution from Alnylam, Amgen, AstraZeneca, Bellerophon, BMS, Celladon, Gilead, GSK, Ionis, Lone Star Heart, Mesoblast, MyoKardia, NIH/NHLBI, Novartis, Sanofi Pasteur, Theracos,  and have consulted for Akros, Alnylam, Amgen, AstraZeneca, Bayer, BMS, Corvia, Gilead, GSK, Ironwood, Merck, Novartis, Pfizer, Roche, Takeda, Theracos, Quantum Genetics,  Cardurion, AoBiome, Janssen, Cardiac Dimensions. None of these grants or relationships funded or played a role in these analyses. 


Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk 

Sara B. SeidelmannElena FeofanovaBing YuNora FranceschiniBrian ClaggettMikko KuokkanenHannu PuolijokiTapani EbelingMarkus PerolaVeikko SalomaaAmil ShahJosef CoreshElizabeth SelvinCalum A. MacRaeSusan ChengEric Boerwinkle and Scott D. Solomon

Journal of the American College of Cardiology


Oct 2, 2018 @ 4:12 pm




The information on is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.


Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.